December 23, 2024
2 min watch
Save
VIDEO: Major response rate for revumenib in KMT2A acute leukemia
In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting 2024 that examined the use of menin inhibitors in patients with leukemia.
DeAngelo, chief of the division of leukemia at Dana-Farber Cancer Institute, highlighted a phase 2 study of revumenib (Revuforj, Syndax Pharmaceuticals) in patients with relapsed or refractory KMT2A acute leukemia.
“These are really exciting results with single-agent therapy. It represents a new field that’s being developed with lots of players — not just revumenib, but also other menin inhibitors now are in development,” DeAngelo said.
Reference:
- Aldoss I, et al. Abstract 211. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
DeAngelo reports numerous ties to industry.
Read more about